The evaluation committee has prepared final draft guidance (FDG) on Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) and submitted it to NICE.
The FDG has been sent to consultees for this evaluation who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the evaluated technology in the NHS in England.
Please note that the appeal period for this evaluation will close at 5pm, 30 March 2023.
This page was last updated: